Case Report
BibTex RIS Cite
Year 2018, Volume: 5 Issue: 12, 390 - 392, 30.12.2018
https://doi.org/10.17546/msd.484778

Abstract

References

  • 1. Gertz MA. Waldenström macroglobulinemia: 2013 update on diagnosis, risk stratification, and management. American journal of hematology. 2013;88(8):703-11.
  • 2. Castillo JJ, Olszewski AJ, Cronin AM, Hunter ZR, Treon SP. Survival trends in Waldenström macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database. Blood. 2014;123(25):3999-4000.
  • 3. Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y, et al. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. New England Journal of Medicine. 2012;367(9):826-33.
  • 4. Varettoni M, Zibellini S, Defrancesco I, Ferretti VV, Rizzo E, Malcovati L, et al. Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance. haematologica. 2017;102(12):2077-85.
  • 5. Treon SP, Ioakimidis L, Soumerai JD, Patterson CJ, Sheehy P, Nelson M, et al. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. Journal of Clinical Oncology. 2009;27(23):3830.
  • 6. Dao C, Zittoun R, Diebold J, Cadiou M, Reynes M, Gaudric M, et al. Sarcomatous and leukemic forms of Waldenström's macroglobulinemia. La semaine des hopitaux: organe fonde par l'Association d'enseignement medical des hopitaux de Paris. 1975;51(48):2935-42.

Waldenstrom macroglobulinemia presenting as plasma cell leukemia associated with hyperviscosity syndrome

Year 2018, Volume: 5 Issue: 12, 390 - 392, 30.12.2018
https://doi.org/10.17546/msd.484778

Abstract





Objective: Waldenstrom
macroglobulinemia (WM) is a rare indolent neoplastic disease characterized by
a wide range of clinical presentations related to the direct tumor
infiltration. The disease is characterized by monoclonal immunoglobulin M
protein in the serum and infiltration of bone marrow with lymphoplasmacytic
cells.


Case report: We,
herein, present an unusual case of WM. A 77-year-old woman admitted to the
hospital with fatigue, anorexia, and fever. She had white blood cell
elevation and splenomegaly. The patient had no peripheral lymphadenopathy. A
large number of plasmablast-like cells were seen in the peripheral blood
smear. Laboratory studies revealed a white blood cell count of 54.8 × 103/µl,
hemoglobin level of 8.2 g/dl and platelet count was 120 × 103/µl. The
diagnosis of WM was established after immunohistochemical analysis of the
patient's bone marrow that revealed the presence of a
lymphoid/lymphoplasmacytoid-like bone marrow infiltrate along with an
elevated serum IgM level. The patient responded to the chemotherapy both
clinically and serologically. This case is unusual since numerous plasmablast
like cells were seen in peripheral blood smear like plasma cell leukemia at
the admission to the hospital.


Conclusion: This
is the case report of a patient with Waldenstrom macroglobulinemia presenting
like plasma cell leukemia in the first admission adding to the spectrum of
clinical presentations seen in this disease. This adds to the wide variety of
clinical presentations of Waldenstrom macroglobulinemia.


References

  • 1. Gertz MA. Waldenström macroglobulinemia: 2013 update on diagnosis, risk stratification, and management. American journal of hematology. 2013;88(8):703-11.
  • 2. Castillo JJ, Olszewski AJ, Cronin AM, Hunter ZR, Treon SP. Survival trends in Waldenström macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database. Blood. 2014;123(25):3999-4000.
  • 3. Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y, et al. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. New England Journal of Medicine. 2012;367(9):826-33.
  • 4. Varettoni M, Zibellini S, Defrancesco I, Ferretti VV, Rizzo E, Malcovati L, et al. Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance. haematologica. 2017;102(12):2077-85.
  • 5. Treon SP, Ioakimidis L, Soumerai JD, Patterson CJ, Sheehy P, Nelson M, et al. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. Journal of Clinical Oncology. 2009;27(23):3830.
  • 6. Dao C, Zittoun R, Diebold J, Cadiou M, Reynes M, Gaudric M, et al. Sarcomatous and leukemic forms of Waldenström's macroglobulinemia. La semaine des hopitaux: organe fonde par l'Association d'enseignement medical des hopitaux de Paris. 1975;51(48):2935-42.
There are 6 citations in total.

Details

Primary Language English
Subjects Health Care Administration
Journal Section Case Reports
Authors

Rafiye Çiftçiler 0000-0001-5687-8531

Arzu Sağlam

Elifcan Aladağ This is me

İbrahim Celalettin Haznedaroğlu This is me

Publication Date December 30, 2018
Published in Issue Year 2018 Volume: 5 Issue: 12

Cite

APA Çiftçiler, R., Sağlam, A., Aladağ, E., Haznedaroğlu, İ. C. (2018). Waldenstrom macroglobulinemia presenting as plasma cell leukemia associated with hyperviscosity syndrome. Medical Science and Discovery, 5(12), 390-392. https://doi.org/10.17546/msd.484778
AMA Çiftçiler R, Sağlam A, Aladağ E, Haznedaroğlu İC. Waldenstrom macroglobulinemia presenting as plasma cell leukemia associated with hyperviscosity syndrome. Med Sci Discov. December 2018;5(12):390-392. doi:10.17546/msd.484778
Chicago Çiftçiler, Rafiye, Arzu Sağlam, Elifcan Aladağ, and İbrahim Celalettin Haznedaroğlu. “Waldenstrom Macroglobulinemia Presenting As Plasma Cell Leukemia Associated With Hyperviscosity Syndrome”. Medical Science and Discovery 5, no. 12 (December 2018): 390-92. https://doi.org/10.17546/msd.484778.
EndNote Çiftçiler R, Sağlam A, Aladağ E, Haznedaroğlu İC (December 1, 2018) Waldenstrom macroglobulinemia presenting as plasma cell leukemia associated with hyperviscosity syndrome. Medical Science and Discovery 5 12 390–392.
IEEE R. Çiftçiler, A. Sağlam, E. Aladağ, and İ. C. Haznedaroğlu, “Waldenstrom macroglobulinemia presenting as plasma cell leukemia associated with hyperviscosity syndrome”, Med Sci Discov, vol. 5, no. 12, pp. 390–392, 2018, doi: 10.17546/msd.484778.
ISNAD Çiftçiler, Rafiye et al. “Waldenstrom Macroglobulinemia Presenting As Plasma Cell Leukemia Associated With Hyperviscosity Syndrome”. Medical Science and Discovery 5/12 (December 2018), 390-392. https://doi.org/10.17546/msd.484778.
JAMA Çiftçiler R, Sağlam A, Aladağ E, Haznedaroğlu İC. Waldenstrom macroglobulinemia presenting as plasma cell leukemia associated with hyperviscosity syndrome. Med Sci Discov. 2018;5:390–392.
MLA Çiftçiler, Rafiye et al. “Waldenstrom Macroglobulinemia Presenting As Plasma Cell Leukemia Associated With Hyperviscosity Syndrome”. Medical Science and Discovery, vol. 5, no. 12, 2018, pp. 390-2, doi:10.17546/msd.484778.
Vancouver Çiftçiler R, Sağlam A, Aladağ E, Haznedaroğlu İC. Waldenstrom macroglobulinemia presenting as plasma cell leukemia associated with hyperviscosity syndrome. Med Sci Discov. 2018;5(12):390-2.